Health and Fitness Health and Fitness
Fri, October 1, 2010
[ Fri, Oct 01st 2010 ] - Market Wire
DaVita Inc. Announces Offering of $1.45 Billion Senior Notes
Thu, September 30, 2010
[ Thu, Sep 30th 2010 ] - Market Wire
United EcoEnergy Corp. Announces Name Change to aUnited Health Products, Inc.a
[ Thu, Sep 30th 2010 ] - Market Wire
PPD Opens Office in Novosibirsk, Russia
[ Thu, Sep 30th 2010 ] - Market Wire
Wright Medical Announces Resolution of Government Investigation
[ Thu, Sep 30th 2010 ] - Market Wire
Elan Corporation Plc Announces Expiration of Asse .. to $186,000,000 of 8 7/8% Senior Fixed Rate Notes
[ Thu, Sep 30th 2010 ] - Market Wire
IntegraMed® Q3 and Q4 Results Expected to Be Imp .. c Start-Up Costs and Several Unanticipated Events
[ Thu, Sep 30th 2010 ] - Market Wire
WellCare to Report Third Quarter 2010 Results on November 4
[ Thu, Sep 30th 2010 ] - Market Wire
Advaxis Investor Conference Call Summary
[ Thu, Sep 30th 2010 ] - Market Wire
ANAVEX APPOINTS DAVID TOUSLEY AS CFO
[ Thu, Sep 30th 2010 ] - Market Wire
Northstar Healthcare Completes Private Placement
[ Thu, Sep 30th 2010 ] - Market Wire
Teva Provides Update on Status of Neutrovala" (G- .. ation Submitted to the U.S. Food and Drug Adminis
[ Thu, Sep 30th 2010 ] - Market Wire
Cubist Pharmaceuticals to Participate in Panel Discussion at Citia?s 5th Annual Biotech Day
[ Thu, Sep 30th 2010 ] - Market Wire
Impax Laboratories to Present at the Jefferies 20 .. bal SpecPharma and European Healthcare Conference
[ Thu, Sep 30th 2010 ] - Market Wire
CellCyte Genetics Corporation Appointments Fred Mill as Vice President of Manufacturing
[ Thu, Sep 30th 2010 ] - Market Wire
RXi Pharmaceuticals to Webcast Presentation at the 9th Annual BIO Investor Forum
[ Thu, Sep 30th 2010 ] - Market Wire
Bond Labs' NDS Expands Inventory Warehousing at Leading National Retailer
[ Thu, Sep 30th 2010 ] - Market Wire
BioSante Pharmaceuticals to Present at the Bio Investor Forum
[ Thu, Sep 30th 2010 ] - Market Wire
Abiomed Announces Specialized Partner Program for .. n the Treatment of Emergent Cardiac Care Patients
[ Thu, Sep 30th 2010 ] - Market Wire
AVEO Pharmaceuticals Regains Worldwide Rights to .. Commercialize Anti-HGF Antibody Candidate AV-299
[ Thu, Sep 30th 2010 ] - Market Wire
Teva and OncoGenex Announce Initiation of Second .. Custirsen in Men with Metastatic Prostate Cancer
[ Thu, Sep 30th 2010 ] - Market Wire
Dr. Daniel L. Farkas, Chairman and CEO of Spectra .. ed an Invited Talk at an International Scientific
Wed, September 29, 2010
[ Wed, Sep 29th 2010 ] - Market Wire
Dyax and CMIC Co., Ltd. Announce Partnership to D .. utaneous DX-88 (ecallantide) for Hereditary Angio
[ Wed, Sep 29th 2010 ] - Market Wire
LecTec Corporation Announces Orders Provided by United States District Court
[ Wed, Sep 29th 2010 ] - Market Wire
Elan to Present at the Jefferies 2010 Global SpecPharma and European Healthcare Conference
[ Wed, Sep 29th 2010 ] - Market Wire
Girard Gibbs LLP Files Class Action Lawsuit Against Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)
[ Wed, Sep 29th 2010 ] - Market Wire
Baxter Receives Approval For PREFLUCEL Seasonal Influenza Vaccine in Austria
[ Wed, Sep 29th 2010 ] - Market Wire
Covidien plc maakt vierdekwartaalcijfers bekend op 9 november 2010
[ Wed, Sep 29th 2010 ] - Market Wire
Santarus and Cosmo Announce Positive Top-Line Res .. cal Study Evaluating Budesonide MMX in Ulcerative
[ Wed, Sep 29th 2010 ] - Market Wire
Health Management Associates, Inc. to Present at .. e Deutsche Bank 2010 Leveraged Finance Conference
[ Wed, Sep 29th 2010 ] - Market Wire
Affymax to Present at BIO Investor Forum

Affymax to Present at BIO Investor Forum


Published on 2010-09-29 13:10:16 - Market Wire
  Print publication without navigation


PALO ALTO, Calif.--([ BUSINESS WIRE ])--Affymax, Inc. (Nasdaq: AFFY) today announced that Arlene Morris, the company's chief executive officer, will present at the 9th Annual BIO Investor Forum on Tuesday, October 5 at 2:30 p.m. PT (5:30 p.m. ET).

A live webcast of the presentation will be available on the investors section of the Company's website at [ www.affymax.com ]. A replay will also be available for 30 days following the presentation.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax's product candidate, Hematide(TM)/peginesatide, recently completed Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure. For additional information, please visit [ www.affymax.com ].

Contributing Sources